Treatment of Latent Tuberculosis Infection: Renewed Opportunity for Tuberculosis Control
Open Access
- 1 July 2000
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (1), 120-124
- https://doi.org/10.1086/313891
Abstract
New recommendations for targeted tuberculin testing and treatment of latent tuberculosis (TB) infection have recently been published. Changes in nomenclature from screening to targeted tuberculin testing and from preventive therapy to treatment of latent TB infection (LTBI) are intended to promote more widespread implementation by programs and health care providers. Targeted tuberculin testing is designed to identify persons at high risk for TB and is discouraged for persons at low risk. New recommendations for treatment of LTBI in both human immunodeficiency virus (HIV)–infected and HIV-uninfected patients include isoniazid for 9 months as the preferred regimen: isoniazid for 6 months based on local program conditions, rifampin and pyrazinamide for 2 months, and rifampin for 4 months. Treatment monitoring now places greater emphasis on clinical, rather than routine, laboratory monitoring. More widespread implementation of targeted tuberculin testing and treatment of LTBI is an important control strategy that will enhance efforts to eliminate TB in the United States.Keywords
This publication has 20 references indexed in Scilit:
- Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized TrialJama-Journal Of The American Medical Association, 2000
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infectionThe Lancet, 1998
- A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency VirusThe New England Journal of Medicine, 1997
- A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for TuberculosisThe New England Journal of Medicine, 1997
- Isoniazid preventive therapy for tuberculosis in HIV-1-infected adultsAIDS, 1997
- Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.American Journal of Respiratory and Critical Care Medicine, 1994
- Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionThe Lancet, 1993
- Isoniazid for the Tuberculin Reactor: Take It or Leave ItAmerican Review of Respiratory Disease, 1988
- The Age Threshold for Isoniazid ChemoprophylaxisJAMA, 1986